Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection
Status:
Completed
Trial end date:
2021-02-02
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, controlled, phase II clinical efficacy study evaluating a
novel Nitric Oxide Releasing Solution (NORS) treatment for the prevention and treatment of
COVID-19 in healthcare workers at risk of infection. Participants will be enrolled into one
of two components of this study. Based on initial swabs/symptoms, volunteers who are COVID-19
negative will be enrolled in the Prevention study and randomized to receive standard
institutional precautions or standard institutional precautions + NORS. Those who are
COVID-19 positive will be enrolled in the open-label Treatment Sub-Study.